Zidovudine/lamivudine

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Imperial College London, Gilead Sciences, Centre Hospitalier Universitaire Saint Pierre

Conditions

HIV InfectionsHIV-1HIV-1 InfectionHTLV-I-associated Myelopathy

Phase 2

Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

CompletedNCT00272480

Imperial College LondonHTLV-I-associated Myelopathy

Start: 1999-11-08End: 2002-07-30Updated: 2021-08-25

Phase 3

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

CompletedNCT00074581

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2005-02-28End: 2015-05-31Updated: 2021-11-05

Phase 4

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada

CompletedNCT00324649

Gilead SciencesHIV-1

Start: 2006-05-31End: 2008-09-30Updated: 2015-08-17

Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting

CompletedNCT01772940

Centre Hospitalier Universitaire Saint PierreHIV-1 Infection

Start: 2008-12-31End: 2011-12-31Updated: 2013-08-26

Related Papers

Prevention of HIV-1 Infection with Early Antiretroviral Therapy

UNC Libraries2020-01-0827 citations

Antiretroviral Therapy for the Prevention of HIV-1 Transmission

New England Journal of Medicine2016-07-181679 citations

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

2014-03-04382 citations

Prevention of HIV-1 infection with early antiretroviral therapy.

2011-07-185149 citations